WallStSmart
ARGX

argenx NV ADR

NASDAQ: ARGX · HEALTHCARE · BIOTECHNOLOGY

$776.02
+0.13% today

Updated 2026-04-29

Market cap
$48.76B
P/E ratio
39.81
P/S ratio
11.51x
EPS (TTM)
$19.60
Dividend yield
—
52W range
$510 – $935
Volume
0.3M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

argenx NV ADR (ARGX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$776.02
Consensus
$1,009.00
+30.02%
2030 Target
$3,358.89
+332.84%
DCF
$2,119.32
+60.62% MoS
19 analysts:
10 Buy2 Hold0 Sell

Management guidance

CEO Karen Massey reaffirmed Vision 2030 strategy targeting 50,000 patients treated (vs 19,000 currently), 10 labeled indications for VYVGART, and five pipeline candidates in Phase 3. Company projects significant revenue growth driven by VYVGART label expansions in MG, CIDP, MMN, myositis, ITP, and Sjögren's disease with multiple Phase 3 readouts in 2026-2027. No specific revenue dollar targets disclosed, but guidance implies multi-billion dollar peak sales trajectory.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$5,598.15
$17.3B Rev × 20x P/S
Base case (2030)
$3,358.89
$17.3B Rev × 12x P/S
Bear case (2030)
$2,239.26
$17.3B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2029 (E)2030 (E)
Revenue$1.2B$2.2B$4.2B$6.1B$8.4B$14.1B$17.3B
Revenue growth—78.6%90.1%43.2%38.4%25.9%22.7%
EPS$-5.33$1.51$17.50$27.90$38.50$62.00$75.50
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$1,194.27$1,642.12$2,761.75$3,358.89

Catalysts & risks

Growth catalysts
+ FDA approval for VYVGART in seronegative gMG (expected May 10, 2026)
+ Phase 3 readouts for VYVGART in myositis, ITP, MMN, and Sjögren's disease (2026-2027)
+ CIDP label expansion and commercial launch acceleration
+ Positive Phase 3 ADAPT OCULUS data for ocular MG already delivered
+ Pipeline advancement with empasiprubart and adimanebart moving through registrational trials
+ Vision 2030 milestone achievement tracking (50K patients, 10 indications)
Key risks
- Clinical trial failures for pipeline expansion indications (myositis, ITP, MMN, Sjögren's)
- Biosimilar competition and pricing pressure on VYVGART in mature markets
- Payer pushback on reimbursement and health economic scrutiny limiting uptake
- Regulatory delays or unfavorable labeling restrictions limiting indication expansion
- Competition from other FcRn inhibitors and alternative immunology therapies
- Valuation reset risk if growth decelerates below consensus 20%+ CAGR expectations
- UplighTED trial setbacks and general execution risks in expanding commercial infrastructure

Methodology

argenx NV ADR's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 19 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.